Effects of disease-modifying drugs on serum neurofilament light chain, chitinase-3-like-1 protein levels, and selected plasmacytoid dendritic cell biomarkers in relapsing-remitting multiple sclerosis. This evidence concerns the gene CHI3L1 and relapsing-remitting multiple sclerosis.